Fisetin is also involved in inhibiting the invasion and migration of A549 NSCLC cells through the inactivation of the extracellular signal-regulated kinase (ERK) signaling pathway and reducing the expression of MMP-2 and urokinase-type plasminogen activator (u-PA) [130]. This evidence concerns the gene PLAU and non-small cell lung carcinoma.